24365-65-9

Basic information

• Product Name: 3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE
• Synonyms: LABOTEST-BB LT00452379;3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE;3-Methyl-3,4-dihydroquinazolin-2(1H)-one;3,4-Dihydro-3-Methyl-2(1H)-quinazolinone 99%;3-Methyl-3,4-dihydro-1H-quinazolin-2-one;3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE(WXG02170)
• CAS NO: 24365-65-9
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Quinazolines
• Mol File: 24365-65-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 200-203 °C(lit.)
• Boiling Point: 366°C at 760 mmHg
• Flash Point: 175.2°C
• Appearance: /
• Density: 1.159g/cm³
• Vapor Pressure: 1.51E-05mmHg at 25°C
• Refractive Index: 1.565
• PKA: 15.05±0.20(Predicted)
• CAS DataBase Reference: 3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE(24365-65-9)
• EPA Substance Registry System: 3,4-DIHYDRO-3-METHYL-2(1H)-QUINAZOLINONE(24365-65-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 24365-65-9(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 13, p. 144, 1970 DOI: 10.1021/jm00295a041Journal of Heterocyclic Chemistry, 25, p. 789, 1988 DOI: 10.1002/jhet.5570250315

InChI:InChI=1/C9H10N2O/c1-11-6-7-4-2-3-5-8(7)10-9(11)12/h2-5H,6H2,1H3,(H,10,12)

Upstream product

• 160354-69-8 2-(methyloxycarbonyl)aminobenzaldehyde 
• 57707-11-6 N-(2-nitrobenzylidene)methanamine 
• 552-89-6 2-nitro-benzaldehyde 
• 56222-08-3 (2-nitrobenzyl)methylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1904-69-4 2-amino-N-methylbenzylamine 
• 4141-08-6 2-Amino-N-methylbenzamid 
• 530-62-1 1,1'-carbonyldiimidazole 
• 117535-91-8 2-amino-N-methylbenzylamine oxalate hydrochloride 
• 57-13-6 urea 

Downstream Products

• 1410782-67-0 4-cyano-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzene-sulfonamide 
• 1410782-58-9 3-methyl-2-oxo-N-phenyl-1,2,3,4-tetrahydro-quinazoline-6-sulfonamide 
• 1410782-59-0 2-chloro-4-fluoro-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide 
• 1410782-60-3 2-methyl-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzene-sulfonamide 
• 1403764-72-6 2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide 
• 1410782-61-4 2-fluoro-N-(3-methyl-2-oxo-1,2,3,4-tetrahydro-quinazolin-6-yl)benzenesulfonamide 
• 328956-24-7 6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one 
• 118621-00-4 3,4-dihydro-3-methyl-6-<4-(4-oxo-4-phenylbutyl)-1-piperazinylcarbonyl>-2(1H)-quinazolinone hydrochloride 
• 118621-04-8 6-(4-Benzyl-piperazine-1-carbonyl)-3-methyl-3,4-dihydro-1H-quinazolin-2-one; hydrochloride 
• 142141-36-4 1-(o-fluorobenzyl)-3-methyl-3,4-dihydro-2(1H)-quinazolinone 
• 328956-25-8 1-benzyl-6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

Quinazolinones, Quinazolinthiones, and Quinazolinimines as Nitric Oxide Synthase Inhibitors: Synthetic Study and Biological Evaluation

The synthesis of different compounds with a quinazolinone, quinazolinthione, or quinazolinimine skeleton and their in vitro biological evaluation as inhibitors of inducible and neuronal nitric oxide synthase (iNOS and nNOS) isoforms are described. These d

Benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds, cardiotonic compositions including the same, and their uses

Compounds of the formula STR1 wherein: z is O or I; X is STR2 a and b are 0, 1, or 2 and a+b=0, 1 or 2; R, R1, R3, R4, R5 and R6 are each independently hydrogen, alkyl or aralkyl; Rn is hydrogen, alkyl, aralkyl, acyl, carbalkoxy, carbamyl, carbalkoxyalkyl, hydroxyalkyl, alkoxyalkyl or amidino; R5 groups on vicinal carbon atoms may together form a carbon-carbon double bond when a or b=2; R groups on vicinal carbon atoms may together form a carbon-carbon double bond when Rn is hydrogen and z=1; R4 and R5 geminal groups may together form a spiro substituent, --(CH2)d --, where d is 2 to 5; R5 and R6 groups may together form a carbon-nitrogen double bond when R3 is hydrogen and a+b=1; R2 is hydrogen or --(CH2)y --Y where y is 1-3; Y is hydrogen, --O--Rα, --S-Rα or STR3 Rα is hydrogen, alkyl, cycloalkyl or acyl; Rβ is hydrogen or alkyl; and Rα and Rβ together may form a 3-7 membered ring which may also contain 0-2 additional hetero atoms selected from N, O and S; provided that when a+b=0 and z is 1, then at least one of Rn, R, R1, R2, R3, R4, R5 and R6 is other than hydrogen; and pharmaceutically acceptable salts thereof, and methods for increasing cardiac contractility using said compounds.